Anagenics (AN1) AI Stock Analysis

• Market Cap: AU$3.69M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: -54.87%
• EPS Growth: 86.17%
• Country: AU
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.02
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.49
• P/FCF Ratio: -1.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ―

Anagenics Limited's overall stock score reflects significant challenges in achieving profitability and managing cash flows effectively. While the company has conservative leverage, its declining equity base and persistent losses raise concerns about financial stability. The absence of key valuation metrics and technical indicators further complicates the investment outlook.

Anagenics Business Overview & Revenue Model

Company Description

Anagenics (AN1) is a biotechnology company focused on developing and commercializing innovative health and wellness products. The company's operations span across sectors such as hair care, skincare, and other personal care products, leveraging scientific research to enhance product efficacy and consumer satisfaction.

How the Company Makes Money

Anagenics generates revenue primarily through the sale of its proprietary health and wellness products in various markets. The company's revenue streams include direct sales to consumers through online platforms, partnerships with retail distributors, and collaborations with industry players to expand product reach. Anagenics may also engage in licensing agreements for its proprietary technologies and formulations, which could contribute to its revenue. Additionally, strategic partnerships with research institutions and other companies in the biotechnology and personal care sectors may play a role in boosting its earnings.

Anagenics Financial Statement Overview

Summary

Anagenics Limited faces challenges in achieving profitability and cash flow sustainability. Despite some revenue growth, the company struggles with negative profit margins and cash flow issues. The balance sheet shows conservative leverage but declining equity base, indicating potential financial instability if losses persist.

Income Statement

Anagenics Limited shows fluctuating revenue growth with an increase from 2023 to 2024, but overall profitability remains a challenge. The net profit margin is negative, and EBIT and EBITDA margins are also unfavorable, indicating operational inefficiencies. Despite some revenue growth, consistent losses impact financial stability.

Balance Sheet

The company's balance sheet indicates a relatively low debt-to-equity ratio, suggesting conservative leverage. However, the equity ratio has deteriorated over time, and the ROE is negative due to ongoing net losses. This reflects a weakened capacity to generate returns on shareholder investments.

Cash Flow

Anagenics Limited has experienced negative operating and free cash flows, although there is a slight improvement in free cash flow. The company struggles to convert net income into cash flow, which indicates difficulties in managing cash effectively. Financing activities have been a significant source of cash inflow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.06M	4.75M	10.80M	9.11M	6.95M	5.82M
Gross Profit	698.51K	2.04M	4.36M	4.05M	3.80M	3.70M
EBITDA	-78.98K	-994.77K	-6.60M	-1.80M	-2.62M	-3.90M
Net Income	-771.75K	-1.24M	-7.49M	-2.67M	-3.65M	-3.39M
Balance Sheet
Total Assets	4.10M	4.10M	6.19M	11.11M	12.92M	13.29M
Cash, Cash Equivalents and Short-Term Investments	395.52K	395.52K	1.62M	2.57M	3.28M	6.73M
Total Debt	848.05K	848.05K	772.64K	654.33K	1.76M	1.43M
Total Liabilities	2.28M	2.28M	3.48M	2.22M	4.64M	2.86M
Stockholders Equity	1.83M	1.83M	2.71M	8.90M	8.29M	10.43M
Cash Flow
Free Cash Flow	-292.14K	-1.58M	-1.84M	-1.83M	-2.59M	-4.19M
Operating Cash Flow	-292.14K	-1.58M	-1.74M	-1.78M	-2.55M	-4.17M
Investing Cash Flow	0.00	0.00	-197.90K	-1.51M	-968.20K	477.53K
Financing Cash Flow	93.24K	345.41K	993.72K	2.56M	73.31K	3.50M

Anagenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
AN1	46 Neutral	AU$3.69M	―	-54.48%	―	-54.87%	86.17%
CLA	37 Underperform	€37.63M	―	-11.03%	―	―	18.92%

Anagenics Corporate Events

Anagenics Limited Reports Improved Cash Flows and Strong Product Performance

Anagenics Limited reported a significant improvement in operating cash flows for the quarter ended June 30, 2025, attributed to a successful business restructuring. The company’s Flouf Factor Growth Tonic has performed well, exceeding sales expectations and potentially generating higher royalties in FY2026. Anagenics is also in discussions with Roquefort Therapeutics regarding midkine antibody licensing. The company believes it has sufficient funds to support operations for the next two quarters without additional equity funding.

Anagenics’ Bouf Haircare Surpasses Sales Expectations, Strengthening Market Position

Anagenics Limited has reported strong performance for Bouf Haircare, a brand developed using its proprietary technology and launched by York Street Brands. Following its successful launch, Bouf Haircare is projected to generate $2.3 million in sales in its first quarter, with expectations to reach $9 million in its first year, surpassing initial forecasts. This success underscores Anagenics’ effective licensing model and the potential for increased profitability through royalty streams, especially with possible international expansion. The launch also highlights York Street Brands’ capability in bringing innovative products to market, further solidifying Anagenics’ position in the industry.

Anagenics’ Haircare Innovation: Bouf’s Successful Launch

Anagenics Limited has announced the successful launch of Bouf, a new haircare brand by York Street Brands, which utilizes Anagenics’ proprietary hair regrowth technology. The launch, which has already achieved significant sales, underscores the strength of Anagenics’ licensing model and the potential for increased profitability through royalty streams. Bouf’s success also highlights York Street Brands’ capability in bringing innovative products to market, with the potential for global expansion.

Anagenics Director Increases Shareholding

Anagenics Limited announced a change in the director’s interest, with Alexander Beard acquiring an additional 55,564 fully paid ordinary shares through an on-market purchase. This acquisition reflects a slight increase in Beard’s indirect shareholding, indicating a potential vote of confidence in the company’s future prospects and stability.

Anagenics Director Increases Shareholding

Anagenics Limited has announced a change in the director’s interest, specifically concerning Alexander Beard. On May 16, 2025, Beard acquired 55,564 ordinary shares through an on-market purchase, increasing his indirect shareholding to 6,195,100 fully paid ordinary shares. This transaction reflects Beard’s continued investment in the company, potentially signaling confidence in Anagenics’ future prospects.

Anagenics Director Increases Shareholding

Anagenics Limited has announced a change in the director’s interest, specifically regarding Alexander Beard’s shareholdings. On May 14, 2025, Beard increased his indirect shareholding by purchasing 226,881 fully paid ordinary shares, bringing his total indirect holdings to 6,139,536 shares. This transaction was conducted through an on-market purchase, reflecting a strategic move by the director to increase his stake in the company.

Anagenics Director Increases Shareholdings, Signaling Confidence

Anagenics Limited has announced a change in the director’s interest, specifically regarding Alexander Beard’s shareholdings. The company disclosed that Beard has increased his indirect shareholding by purchasing a total of 2,963,488 fully paid ordinary shares over three days, resulting in a new total of 5,912,655 shares held indirectly. This on-market purchase indicates Beard’s continued confidence in the company’s prospects, potentially impacting investor sentiment positively.

Anagenics Director Increases Shareholding

Anagenics Limited has announced a change in the director’s interest notice, specifically concerning Alexander Beard. On May 5, 2025, Beard acquired 1,734,067 ordinary shares through an on-market purchase, increasing his indirect shareholding to 2,949,167 fully paid ordinary shares. This transaction signifies a notable increase in Beard’s investment in the company, potentially indicating confidence in Anagenics’ future prospects.